Cargando…

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis

APX001 is a first-in-class, intravenous and orally available, broad-spectrum antifungal agent in clinical development for the treatment of life-threatening invasive fungal infections. The half-life of APX001A, the active moiety of APX001, is significantly shorter in mice than in humans (1.4 to 2.75...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yanan, Lee, Min Hee, Paderu, Padmaja, Lee, Annie, Jimenez-Ortigosa, Cristina, Park, Steven, Mansbach, Robert S., Shaw, Karen Joy, Perlin, David S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153843/ https://www.ncbi.nlm.nih.gov/pubmed/30012766 http://dx.doi.org/10.1128/AAC.00425-18

Ejemplares similares

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
por: Hager, Christopher L., et al.
Publicado: (2018)

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018)

Differential Regulation of Echinocandin Targets Fks1 and Fks2 in Candida glabrata by the Post-Transcriptional Regulator Ssd1
por: Healey, Kelley R., et al.
Publicado: (2020)

Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
por: Larkin, Emily, et al.
Publicado: (2017)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
por: Viriyakosol, Suganya, et al.
Publicado: (2019)

Novel FKS1 and FKS2 modifications in a high-level echinocandin resistant clinical isolate of Candida glabrata
por: Hou, Xin, et al.
Publicado: (2019)

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
por: Alkhazraji, Sondus, et al.
Publicado: (2020)

752. Decreased Echinocandin Resistance among Candida glabrata over an Eleven-Year Period at a University Hospital
por: Raabe, Nathan, et al.
Publicado: (2022)

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
por: Kapoor, Mili, et al.
Publicado: (2019)

Echinocandin-resistant Candida tropicalis Bloodstream Infections
por: Sfeir, Maroun, et al.
Publicado: (2017)

Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model
por: Zhao, Yanan, et al.
Publicado: (2017)

Histone Acetylation Regulator Gcn5 Mediates Drug Resistance and Virulence of Candida glabrata
por: Yu, Shuying, et al.
Publicado: (2022)

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
por: Sandison, Taylor, et al.
Publicado: (2017)

Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
por: Ong, Voon, et al.
Publicado: (2017)

1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P, et al.
Publicado: (2019)

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
por: James, Kenneth D., et al.
Publicado: (2017)

Absorption, Distribution, and Excretion of (14)C-APX001 after Single-Dose Administration to Rats and Monkeys
por: Mansbach, Robert, et al.
Publicado: (2017)

Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
por: Sharp, Marc, et al.
Publicado: (2017)

Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
por: Healey, Kelley R., et al.
Publicado: (2018)

Candidiasis by Candida glabrata, Candida nivariensis and Candida bracarensis in Galleria mellonella: Virulence and Therapeutic Responses to Echinocandins
por: Hernando-Ortiz, Ainara, et al.
Publicado: (2021)

Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants
por: Cheung, Yuk-Yam, et al.
Publicado: (2017)

Analysis of molecular resistance to azole and echinocandin in Candida species in patients with vulvovaginal candidiasis
por: Lotfali, Ensieh, et al.
Publicado: (2022)

CD101: a novel long‐acting echinocandin
por: Zhao, Yanan, et al.
Publicado: (2016)

APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2017)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

Genetic Drivers of Multidrug Resistance in Candida glabrata
por: Healey, Kelley R., et al.
Publicado: (2016)

CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms
por: Chandra, Jyotsna, et al.
Publicado: (2018)

Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis
por: Schell, Wiley A, et al.
Publicado: (2017)

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China
por: Ning, Yating, et al.
Publicado: (2022)

Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies
por: Sfeir, Maroun M., et al.
Publicado: (2020)

In Vitro Interactions of Echinocandins with Triazoles Against Multidrug-Resistant Candida auris
por: Badalii, Hamid
Publicado: (2017)

The Gastrointestinal Tract Is a Major Source of Echinocandin Drug Resistance in a Candida glabrata Colonization Mouse Model
por: Healey, Kelley, et al.
Publicado: (2017)

Two Sequential Clinical Isolates of Candida glabrata with Multidrug-Resistance to Posaconazole and Echinocandins
por: Wang, Qiqi, et al.
Publicado: (2021)

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data
por: Zhao, Yanan, et al.
Publicado: (2020)

726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation
por: Yeoh, Siang Fei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nk8lv48fhp4edtcm1o028a3e24